Sulfasalazine attenuates staphylococcal enterotoxin B-induced immune responses

Toxins

Volumn 7, Issue 2, 2015, Pages 553-559

  Krakauer, Teresa ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Inflammatory cytokines; Staphylococcal enterotoxin B; Sulfasalazine

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; SALAZOSULFAPYRIDINE; STAPHYLOCOCCUS ENTEROTOXIN B; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; ENTEROTOXIN; ENTEROTOXIN A, STAPHYLOCOCCAL; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; QUANTITATIVE ASSAY; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; T LYMPHOCYTE ACTIVATION; CELL CULTURE TECHNIQUE; DOSE RESPONSE; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MONONUCLEAR CELL; T LYMPHOCYTE;

STAPHYLOCOCCUS AUREUS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROTOXINS; HUMANS; LEUKOCYTES, MONONUCLEAR; STAPHYLOCOCCUS AUREUS; SULFASALAZINE; T-LYMPHOCYTES;

EID: 84923213980     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins7020553     Document Type: Article

References (24)

1. Kotzin, B.L.; Leung, D.Y.M.; Kappler, J.; Marrack, P. Superantigens and their potential role in human disease. Adv. Immunol. 1993, 54, 99–166.
2. Langley, R.; Patel, D.; Jackson, N.; Clow, F.; Fraser, J.D. Staphylococcal superantigen super-domains in immune evasion. Crit. Rev. Immunol. 2010, 30, 149–165.
3. DeVries, A.S.; Lesher, L.; Schlievert, P.M.; Rogers, T.; Villaume, L.G.; Danila, R.; Lynfield, R. Staphylococcal toxic shock syndrome 2000–2006: Epidemiology, clinical features, and molecular characteristics. PLoS One 2011, 6, doi:10.1371/journal.pone.0022997.
4. Carlsson, R.; Fischer, H.; Sjogren, H.O. Binding of staphylococcal enterotoxin A to accessory cells is a requirement for its ability to activate human T cells. J. Immunol. 1988, 140, 2484–2488.
5. Choi, Y.; Kotzin, B.; Hernon, L.; Callahan, J.; Marrack, P.; Kappler, J. Interaction of Staphylococcus aureus toxin “superantigens” with human T cells. Proc. Natl. Acad. Sci. USA 1989, 86, 8941–8945.
6. Jupin, C.; Anderson, S.; Damais, C.; Alouf, J.E.; Parant, M. Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon. J. Exp. Med. 1988, 167, 752–761.
7. Miethke, T.; Wahl, C.; Heeg, K.; Echtenacher, B.; Krammer, P.H.; Wagner, H. Superantigen mediated shock: A cytokine release syndrome. Immunobiology 1993, 189, 270–284.
8. Neumann, B.; Engelhardt, B.; Wagner, H.; Holzmann, B. Induction of acute inflammatory lung injury by staphylococcal enterotoxin B. J. Immunol. 1997, 158, 1862–1871.
9. Fraser, J.D.; Proft, T. The bacterial superantigen and superantigen-like proteins. Immunol. Rev. 2008, 225, 226–243.
10. Lappin, E.; Ferguson, A.J. Gram-positive toxic shock syndromes. Lancet Infect. Dis. 2009, 9, 281–290.
11. Krakauer, T.; Buckley, M.; Fisher, D. Proinflammatory mediators of toxic shock and their correlation to lethality. Mediators Inflamm. 2010, doi:10.1155/2010/517594.
12. Krakauer, T.; Vilcek, J.; Oppenheim, J.J. Proinflammatory cytokines: TNF and IL-1 families, chemokines, TGFß and others. In Fundamental Immunology, 4th ed.; Paul, W., Ed.; Lippincott-Raven: Philadelphia, PA, USA, 1998; pp. 775–811.
13. Mattsson, E.; Herwald, H.; Egsten, A. Superantigen from Staphylococcus aureus induce procoagulant activity and monocyte tissue factor expression in whole blood and mononuclear cells via IL-1β. J. Thromb. Haemost. 2003, 1, 2569–2575.
14. Darenberg, J.; Soderquist, B.; Normark, B.H.; Norrby-Teglund, A. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: Implications for therapy of toxic shock syndrome. Clin. Infect. Dis. 2004, 38, 836–842.
15. Krakauer, T. Update on staphylococcal superantigen-induced signaling pathways and therapeutic interventions. Toxins 2013, 5, 1629–1654.
16. Rains, C.P.; Noble, S.; Faulds, D. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs. 1995, 50, 137–156.
17. Hoult, J.R. Pharmacological and biochemical actions of sullphasalazine. Drugs 1986, 32, 18–26.
18. Gadangi, P.; Longaker, M.; Naime, D.; Levin, R.I.; Recht, P.A.; Montesinos, M.C.; Buckley, M.T.; Carlin, G.; Cronstein, B.N. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J. Immunol. 1996, 156, 1937–1941.
19. Vallabhapurapu, S.; Karin, M. Regulation and function of NFκB transcription factors in the immune system. Annu. Rev. Immunol. 2009, 27, 693–733.
20. Krakauer, T. Nuclear factor-κB: Fine-tuning a central integrator of diverse biologic stimuli. Int. Rev. Immunol. 2008, 27, 286–292.
21. Lappas, M.; Yee, K.; Permezel, M.; Rice, G.E. Sulfasalazine and BAY 11–7082 interfere with the nuclear factor-κB and IκB kinase pathway to regulate the release of proinflammatory cytokines from human adipose tissue and skeletal muscle in vitro. Endocrinology 2005, 146, 1491–1497.
22. Barnes, B.J.; Karin, M. Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory disease. N. Engl. J. Med. 1997, 336, 1066–1071.
23. Trede, N.S.; Castigli, E.; Geha, R.S.; Chatila, T. Microbial superantigens induce NF-kappa B in the human monocytic cell line THP-1. J. Immunol. 1993, 150, 5604–5610.
24. Krakauer, T. Suppression of endotoxin- and staphylococcal exotoxin-induced cytokines and chemokines by a phospholipase C inhibitor in human peripheral blood mononuclear cells. Clin. Diagn. Lab. Immunol. 2001, 8, 449–453.